Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.

In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.